TVTX

Travere Therapeutics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↑ 8/10
  • Value↓ 0/10
Travere Therapeutics sales and earnings growth
TVTX Growth
Good
  • Revenue Y/Y↑ 96.03%
  • EPS Y/Y↑ 92.11%
  • FCF Y/Y↑ 85.69%
Travere Therapeutics gross and profit margin trends
TVTX Profitability
Neutral
  • Gross margin ↑ 98.60%
  • EPS margin↓ -4.00%
  • ROIC 5Y↓ -22.42%
Travere Therapeutics net debt vs free cash flow
TVTX Risk
Poor
  • Debt / Equity↑ 3.3
  • Debt / FCF↑ 8.6
  • Interest coverage↓ -1.0

Travere Therapeutics stock volatility is in-line with the overall market. We give it a Poor risk rating.

↗ More Biotechnology stocks